HomeMost PopularInvestingFurious Frustrations: CMA Sees Organic Growth and High Expenses Crush Financial Prospects

Furious Frustrations: CMA Sees Organic Growth and High Expenses Crush Financial Prospects

Actionable Trade Ideas

always free

Hitting the Numbers

Comerica Incorporated’s (CMA) top-line growth gains momentum from soaring rates and an escalating net interest income (NII) coupled with a surge in loan balances. This provides sustenance in capital distributions. Despite these gains, building expenses and a concentrated commercial loan portfolio wield tremendous pressure.

Financial Pulse

Comerica’s ability to generate income has seen considerable uplift due to loan growth in recent years. This surge has strengthened the loan pipeline, indicating a prospective enhancement in loan balances in the near future, revealing management’s anticipation of a 7% upsurge in average loans in 2023.

Heightened loan balances have propelled Comerica’s NII, unfailingly contributing to top-line expansion. With the Federal Reserve set to maintain high interest rates in the near term, NII and net interest margin are poised for sustained growth. Nevertheless, heightened funding costs will exert pressure on both NII and net interest margin. Projections by the company hint at an expected 1-2% increase in NII in 2023.

Stumbling Blocks

Comerica’s unyielding focus on enhancing operational efficiency prodded the launch of GEAR Up initiatives in the middle of 2016, eventually leading to a surge in the efficiency ratio and return on equity. The company’s persistent diligence in revamping its offerings, refining sales tools, training, and enriching customer analytics sets a solid stage for robust revenue growth.

Comerica’s robust liquidity profile is underscored by its substantial cash reserves and a whopping $20.3 billion capacity left in its discount window as opposed to its commitments, ensuring the sustainability of capital distributions. This element holds the potential to fan investors’ confidence in the stock.

However, the ascending cost base poses a red flag for CMA. The company’s non-interest expenditures have been spiraling with the escalation in salaries and benefits expenditure. Such ascending expenses are anticipated to impede bottom-line growth in the forthcoming quarters, with management estimating an 11% surge in expenses in 2023.

Shaky Ground

Comerica boasts substantial exposure to commercial and commercial mortgage loans, comprising 80% of total loans as of Sep 30, 2023. Commercial lending is susceptible to rapid fluctuations in the current macroeconomic landscape, and further turbulence could spell major trouble for CMA’s financials.

Additionally, the notable business presence of Comerica in California and Michigan, amid an increasingly challenging economic environment over the recent years, leaves the company susceptible to potential economic turmoil in the region. This geographic concentration adds a concerning layer of vulnerability to the company.

Seeking Greener Pastures

While CMA trails with a Zacks Rank #3 (Hold), the stock has incurred a 0.7% loss over the past three months, in stark contrast to the industry’s surge of 8.8%.

Zacks Investment Research
Image Source: Zacks Investment Research

Finding Promise Elsewhere

Better prospects may lie with other stocks in the banking arena. Both JPMorgan Chase & Co. (JPM) and Park National Corporation (PRK) currently carry a Zacks Rank #1 (Strong Buy), providing alternatives for potential investors looking to navigate away from Comerica’s tumultuous landscape.

The earnings projection for JPM in 2023 has seen an upward revision of 4.9% over the past 60 days, elucidating a robust 8% surge in shares over the past three months. On the other hand, the Zacks Consensus Estimate for PRK’s current-year earnings has undergone a 6.2% upward revision in the past 30 days, paving the way for a solid 15.7% appreciation in shares over the past three months.

Shining Lights

Amidst thousands of stocks vying for investor attention, five selective Zacks experts have each pinpointed their top choice offering the potential to soar by +100% or more in the ensuing months. Director of Research Sheraz Mian has singled out a project credited with a “watershed medical breakthrough,” boasting a promising pipeline that could revolutionize the landscape for patients grappling with liver, lung, and blood-related ailments. This presents a timely investment opportunity amidst a bear market. It holds the potential to rival or surpass other recent Stocks Set to Double, such as Boston Beer Company, soaring by +143.0% in just over 9 months, and NVIDIA, which witnessed a blistering +175.9% spike in just a year.

Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report
Comerica Incorporated (CMA) : Free Stock Analysis Report
Park National Corporation (PRK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.